ArticleLa Radiologia medica2026
Impact of radiotherapy timing on survival and radiotoxicity outcomes in localized prostate cancer: a retrospective cohort study.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeNearly 30% of prostate cancer patients undergo external beam radiotherapy (EBRT) as first-line therapy; however, 27-53% of localized cases experience recurrence or progression. Circadian rhythm regulates 24-h biological cycles, including cell growth, DNA repair, metabolism, and immune function. Clinical evidence suggests that radiotherapy efficacy and toxicity may vary by time of day.
methodsThis retrospective cohort study evaluated whether EBRT time of day affects treatment outcomes and toxicity in localized prostate cancer. A total of 224 patients treated between 2012 and 2021 at the Portuguese Oncology Institute of Porto were analyzed. Patients were divided into two groups based on the receiver operating characteristic (ROC) curve for metastasis-free survival using treatment time (before or after 12:45PM), and in a secondary analysis, morning (08:30-11:30AM) versus afternoon (03:00-08:00PM). Survival outcomes and toxicities were assessed using Kaplan-Meier curves, Cox proportional hazards models, and binary logistic regression. Propensity score matching was used to adjust for confounding variables.
resultsMorning treatment was significantly associated with a 76% reduced risk of metastasis post-treatment (P = 0.031) and improved 10-year metastasis-free survival (log-rank P = 0.014). Furthermore, patients treated in the morning had significantly lower risks of late grade ≥ 2 gastrointestinal (86% reduction, P = 0.013) and genitourinary (67% reduction, P = 0.003) toxicity.
conclusionDespite the retrospective, single-institution design, our results indicate that EBRT timing significantly influences prostate cancer outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.